| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/06/2008 | WO2008003855A3 Use of 2-benzoyl-imidazopyridines in therapeutics |
| 03/06/2008 | WO2008003854A3 Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics |
| 03/06/2008 | WO2008003484A8 Agent containing chrysin and cholic acid for reducing weight, accelerating lipid catabolism, and/or restricting calories |
| 03/06/2008 | WO2008002902A3 Adenosine a2b receptor antagonists |
| 03/06/2008 | WO2008002614A3 Pseudoazulenyl nitrones |
| 03/06/2008 | WO2008000512A3 Method for identifying crmp modulators |
| 03/06/2008 | WO2008000463A3 Rabeprazole formulation |
| 03/06/2008 | WO2007149873A3 Kv1.5 potassium channel inhibitors |
| 03/06/2008 | WO2007149829A3 Therapeutic compounds |
| 03/06/2008 | WO2007149504A3 Isoalpha acid based protein kinase modulation cancer treatment |
| 03/06/2008 | WO2007147370A3 Pseudoceramides and pharmaceutical and/or cosmetic compositions designed for administration to the skin containing the same |
| 03/06/2008 | WO2007146953A3 Compositions and methods for sirna inhibition of angiogenesis |
| 03/06/2008 | WO2007146823A3 Carbohydrate derivatives of heptanoic acids |
| 03/06/2008 | WO2007146813A3 Pyridinone analogs as cell proliferation inhibitors |
| 03/06/2008 | WO2007146225A3 Heterocyclic aspartyl protease inhibitors |
| 03/06/2008 | WO2007145835A3 Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity |
| 03/06/2008 | WO2007144129A3 Pyrrolidine derivatives useful against diseases that depends on activity of renin |
| 03/06/2008 | WO2007143506A3 Substituted benzimidazole thiophene benzyl ether compounds |
| 03/06/2008 | WO2007142951A3 Oral controlled release formulations of an interleukin-1 beta converting enzyme inihibitor |
| 03/06/2008 | WO2007141392A3 Compositions comprising betulonic acid |
| 03/06/2008 | WO2007141284A3 Treatment of gastrointestinal disorders with cgrp antagonists |
| 03/06/2008 | WO2007141283A3 Salts and crystalline salt forms of an 2-indolinone derivative |
| 03/06/2008 | WO2007140173A3 Methods of maintaining and using a high concentration of dissolved copper on the surface of a useful article |
| 03/06/2008 | WO2007140136A3 Therapeutic cyclopentane derivatives |
| 03/06/2008 | WO2007139943A3 Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders |
| 03/06/2008 | WO2007139808A3 Device for delivery of antifibrotic agents & method |
| 03/06/2008 | WO2007137301A8 Modulation of chrebp expression |
| 03/06/2008 | WO2007137204A3 Methods for the delivery of a beta2 agonist to induce bronchodilation and formulations for use in the same |
| 03/06/2008 | WO2007137000A3 Combination cancer chemotherapy |
| 03/06/2008 | WO2007135461A3 Pharmaceutical compositions comprising implitapide and methods of using same |
| 03/06/2008 | WO2007134867A3 Treating muscular disorders and improving muscular function |
| 03/06/2008 | WO2007133622A3 Selective inhibitors of rock protein kinase and uses thereof |
| 03/06/2008 | WO2007131736A3 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
| 03/06/2008 | WO2007131201A3 Compounds and compositions as hedgehog pathway modulators |
| 03/06/2008 | WO2007131154A3 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| 03/06/2008 | WO2007129274A3 Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350. |
| 03/06/2008 | WO2007128761A3 Uses of dpp-iv inhibitors |
| 03/06/2008 | WO2007125398A3 : sulfonamide compounds as antagonists of the n-type calcium channel |
| 03/06/2008 | WO2007124369A3 Method of inhibiting c kit kinase |
| 03/06/2008 | WO2007121913A3 Pharmaceutical solution formulations for pressurised metered dose inhalers |
| 03/06/2008 | WO2007121088A3 Combinations of therapeutic agents for treating cancer |
| 03/06/2008 | WO2007120606A8 Methods for modulating formation and progression of cellulite |
| 03/06/2008 | WO2007119029A8 Co-crystals of calixarenes and biologically active molecules |
| 03/06/2008 | WO2007117467B1 Use of tm-601 for the diagnosis and treatment of tumors |
| 03/06/2008 | WO2007112028A3 2'-fluoronucleoside phosphonates as antiviral agents |
| 03/06/2008 | WO2007111933A3 Pharmaceutical compositions comprising a hypoglycemic agent and methods of using same |
| 03/06/2008 | WO2007103876A3 Cancer therapeutic |
| 03/06/2008 | WO2007103760A3 Thiazolones for use as pi3 kinase inhibitors |
| 03/06/2008 | WO2007103759A3 Thiazolones for use as pi3 kinase inhibitors |
| 03/06/2008 | WO2007103758A3 Thiazolones for use as pi3 kinase inhibitors |
| 03/06/2008 | WO2007103756A3 Thiazolones for use as pi3 kinase inhibitors |
| 03/06/2008 | WO2007103755A3 Thiazolones for use as pi3 kinase inhibitors |
| 03/06/2008 | WO2007103754A3 Thiazolones for use as pi3 kinase inhibitors |
| 03/06/2008 | WO2007103252A3 Novel crystalline forms of antidiabetic compounds |
| 03/06/2008 | WO2007102999A3 Cb1 antagonists and inverse agonists |
| 03/06/2008 | WO2007100759A3 Method for treating common variable immunodeficiency |
| 03/06/2008 | WO2007100664A3 Modulators of muscarinic receptors |
| 03/06/2008 | WO2007100387A3 Process for preparing tadalafil |
| 03/06/2008 | WO2007096193A3 Radiolabelled carbamates |
| 03/06/2008 | WO2007091106A3 Treatment of duchenne muscular dystrophy |
| 03/06/2008 | WO2007089688A3 Na/k-atpase ligand |
| 03/06/2008 | WO2007082053A3 Trpm2-specific inhibitors |
| 03/06/2008 | WO2007078874A3 Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| 03/06/2008 | WO2007075896A3 Heterocyclic cytokine inhibitors |
| 03/06/2008 | WO2007070434A3 Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes |
| 03/06/2008 | WO2007062101A3 Intraocular pressure-regulated early genes and uses thereof |
| 03/06/2008 | WO2007044032A3 Compositions having a high antiviral and antibacterial efficacy |
| 03/06/2008 | WO2007041156A3 Antibiotic formulations, unit doses, kits, and methods |
| 03/06/2008 | WO2007036920A3 Therapeutic use of polyanhydroglucronic acid |
| 03/06/2008 | WO2007000641A8 Prostaglandin derivatives |
| 03/06/2008 | WO2006127426A8 Insecticidal substituted benzylamino heterocyclic and heteroaryl derivatives |
| 03/06/2008 | WO2006096404A8 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues |
| 03/06/2008 | WO2006050379A3 Modulation of serotonin neurons involving the pet-1 transcriptional control region |
| 03/06/2008 | WO2006047485A3 Methods for lowering hif-1 mediated gene expression |
| 03/06/2008 | WO1999045887A3 Monolithic tablet for controlled drug release |
| 03/06/2008 | US20080058941 Supplemental spine fixation device and method |
| 03/06/2008 | US20080058762 Induction And Maintenance Of Tolerance To Composite Tissue Allografts |
| 03/06/2008 | US20080058733 Antibiotic(s)-polymer combination |
| 03/06/2008 | US20080058713 System for perfusion management |
| 03/06/2008 | US20080058546 Methods for Synthesis of Acyloxyalkyl Derivatives of GABA Analogs |
| 03/06/2008 | US20080058519 Quinazoline ditosylate salt compounds |
| 03/06/2008 | US20080058515 indazolylacrylamide derivatives are useful in the treatment of diseases associated with inappropriate SGK-1 activity |
| 03/06/2008 | US20080058514 ceramide-like inhibitors; novel intermediates formed during the synthesis; Glycosphingolipids |
| 03/06/2008 | US20080058502 Method for preparing microparticles having a selected polymer molecular weight |
| 03/06/2008 | US20080058469 Adhesion Preventive Material |
| 03/06/2008 | US20080058427 Cyclodextrin-based polymers for therapeutics delivery |
| 03/06/2008 | US20080058426 Composition and method for treating psoriasis |
| 03/06/2008 | US20080058425 Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof |
| 03/06/2008 | US20080058424 Novel pharmaceutical formulations of modafinil |
| 03/06/2008 | US20080058423 Melanin concentrating hormone antagonists |
| 03/06/2008 | US20080058422 Using alpha-ketoglutarate , mono- or divalent metal salts of alpha-ketoglutarate and/or ornithine of alpha-ketoglutarate; acting specifically on neoplastic cells with the simultaneous protective activity on the normal cells; synergic action with antineoplastic drugs and simultaneous protective activity |
| 03/06/2008 | US20080058421 Biodegradable solution, spray or mist comprising an organic acidifying agent, a solubilzer, and broad-spectrum microbicidal/germ killing, food-additive anionic surfactants; safe and nontoxic; sanitizing; prevevtion of respiratory system disorders; antiallergens; cleaning compounds; microbiocides |
| 03/06/2008 | US20080058420 A mixture of excipients not promoting the conversion of gabapentin into the corresponding lactamic impurity; including a sliding agent, e.g., calcium phosphate, a lubricant either hydrogenated castor oil or glyceryl tribehenate, and optionally a diluent saccharide; capsules; storage stability; nontoxic |
| 03/06/2008 | US20080058419 Treatment Of Poultry For Increasing The Feed Conversion Rate Or For Reducing The Incidence Of Ascites |
| 03/06/2008 | US20080058418 An emulsion having a continuous liquid phase, an emulsifier; and a discontinuous liquid phase of a blend of polyunsaturated fatty acid source and a dispersant, e.g. a flavanoid,acid, where the weight ratio of the fatty acid source to the dispersant is between 9:1-1:10; nutraceuticals; foods; beverages |
| 03/06/2008 | US20080058417 Enriched Beverages and Methods of Making The Same |
| 03/06/2008 | US20080058416 Administering a ketogenic material to produce a ketosis to provide effects of antidepressants, anxiolytic agents, cognition activators, and/or analgesics; preferred materials produce such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood is raised to 0.1-30 mM. |
| 03/06/2008 | US20080058415 Lipid Preparation for Enhancing Mineral Absorption |
| 03/06/2008 | US20080058414 Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents |
| 03/06/2008 | US20080058413 ester derivatives capable of reverting to the active parent compound following enzymatic or chemical hydrolysis; higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound; epidermoid carcinoma and tumors induced by human papillomavirus (HPV) |